Hims & Hers price target raised to $21 from $18 at Piper Sandler
Piper Sandler analyst Korinne Wolfmeyer raised the firm’s price target on Hims & Hers to $21 from $18 and keeps a Neutral rating on ...
Hims & Hers will start selling a generic weight loss drug
The millennial-skewed telehealth platform Hims & Hers (HIMS) announced Monday that it will start offering customers a generic version of liraglutide, an older GLP-1 weight loss drug, next year. The ...
Hims & Hers Stock Soars: First Generic Weight Loss Drug to Shake Up Billion-Dollar Market
Shares jump over 5% as Hims & Hers unveils plans for the first generic GLP-1--targeting Novo's weight-loss dominance ...
Stocktwits on MSN12h
Hims & Hers Soars Pre-Market After Analysts Boost Price Targets On Strong Q3 Performance
Hims & Hers Health Inc. ($HIMS) rallied nearly 9% in pre-market trading on Tuesday, following the company’s third-quarter ...
Hims & Hers to launch a generic for Novo’s older GLP-1
Hims & Hers Health (HIMS) stock gains after its Q3 2024 results as company plans to launch a generic version of Novo ...
Seeking Alpha23h
Hims & Hers: A Lot More Than Just GLP-1, And It's Proving Its Ability To Grow
Subscriber growth surged 44% y/y to 2.05 million. It's also worth noting that ex-GLP 1 subgrowth would have been 40% y/y, ...
Microdosing Ozempic? Why some people are playing doctor with weight-loss drugs
She’d first heard of Wegovy, a GLP-1 made by Novo Nordisk, from a friend’s success story ... meant having no doctor to turn ...
Hims & Hers shares rally on results, but execs say GLP-1 drug shortage ‘is not abating’
Shares of Hims & Hers Health Inc. rallied after hours on Monday after the wellness platform bumped its full-year sales ...